Greenwich LifeSciences (GLSI) Earnings Date & Reports
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
GLSI is expected to report earnings to rise 1.52% to -33 cents per share on November 16
Q3'26
Est.
$-0.34
Q2'26
Est.
$-0.34
Q1'26
Est.
$-0.33
Q4'25
Beat
by $0.02
Q3'25
Missed
by $0.10
The last earnings report on August 17 showed earnings per share of -33 cents, beating the estimate of -33 cents. With 34.16K shares outstanding, the current market capitalization sits at 272.87M.